While in the early identification and intervention of psychosis-specific instruments and risk criteria have been generated and validated, research into indicated preventive strategies for bipolar I disorder (BD I) has only recently gained momentum. As the first signs of BD I often start before adulthood, such efforts are especially important in the vulnerable pediatric population. Data are summarized regarding the presence and nature of potentially prodromal, that is, subsyndromal, symptoms prior to BD I, defined by first-episode mania, focusing on pediatric patients.
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Highlights
• A clinical prodrome preceding an FEM seems to exist in most patients developing BD I, including attenuated manialike symptoms, depressive symptoms, as well as nonspecific global illness signs, such as decline in social and academic and (or) role functioning. However, no sufficiently predictive risk constellations have been identified so far that could be applied in clinical practice.
• Family history of BD I and presence of syndromal depression, ADHD, disruptive behaviour disorders, and cyclothymic hypersensitive temperamental traits are risk factors for future BD I development, but most subjects exhibiting these traits or states do not seem to develop BD I. This increases the need for the identification of genetic, neuroimaging, neurochemistry, and neurocognition endophenotypes that will further enhance early identification of BD I in subsyndromal phases in the future.
• Clinicians should carefully assess potential BD I risk symptoms in patients with mood spectrum presentations, particularly in youth with MDD or a BD I family history, carefully weighing and monitoring the potential risks and benefits of AD treatment.
B ipolar I disorder markedly impairs behaviour, social, occupational, and physical functioning, and general health. [1] [2] [3] For the pediatric subtypes, adverse consequences are even more severe, including higher rates of treatment refractoriness, psychiatric comorbidities, and functional disability. [4] [5] [6] [7] [8] A major challenge for improved outcomes is the commonly large lag between symptom onset and first correct BD I diagnosis and appropriate treatment. 4, 9 Although the typical illness onset according to the DSM-IV is at around age 20 years, 50% to 67% of people with BD I report first illness signs prior to age 18. 5, 9 Moreover, prepubertal onset is also much more common than in nonaffective psychotic disorders. 10 All of the features mentioned above make BD I a prime condition for early identification and intervention.
To enable the identification of people at high risk for BD I, rating instruments and criteria for the prodrome of BD I, that is, for subsyndromal and subthreshold presentations of BD I, are required. Such instruments and tentative criteria are needed to validate risk criteria in prospective studies and test early interventions, as has been done successfully in psychosis research. [11] [12] [13] [14] However, despite the urgency to move in this direction, these developments have been lagging behind in BD I research until fairly recently. [15] [16] [17] [18] [19] [20] [21] [22] [23] In our paper, we will review several lines of evidence supporting the existence of a BD I prodrome; that is, a sufficiently long phase of beginning symptoms foreshadowing an FEM that would allow for early identification and intervention in a sufficiently large proportion of patients. We focus on data in, and the application to, youth, discussing also conceptual and practical challenges.
Methods
In this narrative review, we examine conceptual and practical problems in defining a BD I prodrome, particularly in youth; summarize the evidence for the presence of a subthreshold, symptomatic prodrome preceding BD I; and, evaluate the current knowledge highlighting the consequences for research and clinical care of youth at possible risk for BD I.
Although, retrospectively, depression may have been the first episode of BD I, the onset of BD I is defined for the purpose of this review diagnostically (rather than biologically, for which data are currently absent) as the onset of an FEM or mixed episode. Moreover, although it is clinically relevant to identify precursor and risk states for BD II or BD NOS, we focus almost exclusively on BD I, as, to date, data are not available to adequately characterize the prodrome, even preceding full mania.
For the purpose of our review, and concordant with the psychosis field, 12 we define prodromal or subsyndromal de risque sont absentes pour la plupart ou en sont aux premiers stades. Il faut plus de travaux pour déterminer des critères de risque clinique élevé valides et suffisamment spécifiques , pour  distinguer les facteurs de risque, endophénotypes, et comorbidités de la symptomatologie  prodromique, et pour mettre au point des interventions propres aux phases qui dosent le risque  de l'intervention avec le risque de transition à la manie et avec l'incapacité fonctionnelle ou la  détresse psychologique. En outre, il faut des études qui déterminent les différences potentielles  de symptômes et de trajectoires prodromiques entre les enfants, les adolescents et les adultes, et  les meilleures interventions pour chaque phase. symptoms and signs as symptomatic illness manifestations that are attenuated versions of a full mania syndrome. In this context, hypomania, cyclothymia, and BD II can all be seen as the latest, most proximal prodrome to BD I. We further define risk factors as biological, environmental, behavioural, emotional, cognitive, or psychological states and events that increase the likelihood of developing BD I, but that are not thought to be part of the symptomatic evolution toward fulfilling current diagnostic criteria. We finally define comorbidities as syndromal manifestations of nonaffective disorders that are distinctly classified under current nosological conventions, even if there may be symptomatic overlap with threshold or subthreshold mania symptoms. We realize that these definitions are preliminary and will likely be revised given new knowledge.
Results
In the past few years, numerous reviews assessed the scarce retrospective and even scarcer prospective literature on prodromal symptoms and signs in adults with BD I. [15] [16] [17] [18] [21] [22] [23] [24] [25] Even more recently, several articles focused specifically on children and adolescents. 19, 20, 26 Across these reviews, the lack of specificity of prodromal symptoms has been bemoaned. The authors cautiously concluded that there is some evidence that prodromal states precede BD I, including in children and adolescents, at least in a sizeable subgroup of people, but that more longitudinal research, including control groups, is needed to establish the definition of the BD I prodrome and to ultimately enable early identification of BD I.
Conceptual and Practical Difficulties With the BD I Prodrome
While the existence of a psychotic prodrome is well documented and validated with criteria that have yielded transition rates to psychosis within 6 months to 3 years of 10% to 40% in criteria-based, at-risk samples, which are high enough to test preventive interventions, 11, 12 the existence of a sufficiently specific BD I prodrome is still debated.
A major challenge for identifying a BD I prodrome, particularly in youth, is the complex, phenomenological definition and course of BD. The DSM-IV-TR 27 does not distinguish between adults and youth. However, BD I in youth seems to differ from adults in several ways, including the onset pattern, symptom and cycling characteristics, as well as interepisode functioning (online eTable 1). [28] [29] [30] [31] Interestingly, Masi et al 10 even report differences between childhood-and adolescent-onset patients. While childhoodonset (before age 12 years) BD I was more frequently associated with male sex and comorbid ADHD and (or) ODD, and a rather subcontinuous course (41.2% episodic), adolescent-onset BD I was more frequently associated with an episodic course (76.8%), indicating also potential differences regarding prodromal states. The frequent comorbidity of BD with ADHD and ODD in youth is complicated by certain symptoms that overlap and can be rated for both conditions (online eTable 2). 31 The large symptomatic and criteria overlap makes it the more important to consider only Criterion B mania symptoms when they are related to Criterion A mood symptoms. However, this can be difficult and the overlap of mania criteria with other conditions and the less episodic course in youth has triggered ongoing debate about whether pediatric and adult BD I are the same conditions, or whether pediatric BD I may be a developmental subtype or misdiagnosed, owing to overlapping symptoms with ADHD, ODD, substance use and (or) experimentation, irritable depression, or life crises. 15, 31, 32 The current definition of mania constitutes the key aspect in this debate. Pediatric mania has been characterized by very rapid, brief, recurrent episodes, either lasting hours to a few days, or constituting the overall impaired baseline functioning. 29, 33, 34 Accordingly, Axelson et al 35 reported that the short duration of episodes in youth, which are shorter than DSM-IV criteria require, was the main reason why they were diagnosed with BD NOS instead of BD I. Further, depending on whether elated mood or irritability is the leading Criterion A symptom, as many as an additional 3 or 4 BD I Criterion B symptoms at suprathreshold severity are required for a diagnosis of mania. 27 This leaves the possibility of still having diagnostically subsyndromal and (or) prodromal stages, despite the presence of either 3 or 4 full severity symptoms that last for more than 1 week.
Further complicating the delineation of mood states, both prodromal and subsyndromal, is that, in youth (different from adults), irritability is both a Criterion A for depression and for mania, 27 and that mixed episodes are frequent. 36 Finally, BD I may begin with depressive episodes or with an FEM and (or) mixed episode. This fact adds further complexity, compared with the psychosis prodrome, which generally is much less episodic and for which presence of only one single attenuated positive symptom is sufficient. Moreover, as mood and behavioural activation are not uncommon and quite nonspecific in childhood and adolescence, they may co-occur in patients at risk for psychosis, but they are not defining symptoms of the attenuated or full syndromal illness expression, as in BD I.
Taken together, these general and developmental characteristics complicate the delineation of normal and abnormal mood states and the attribution of symptoms to a true BD I prodrome, compared with comorbid or unrelated conditions, crises, or extremes of normal development. However, it remains to be seen if, and to what degree, these mood episodes or comorbid conditions are risk or vulnerability markers for the future development of BD I, even if they may not (yet) represent subsyndromal illness expressions. A delineation of risk markers and prodromal symptoms will require much more research, as will the discovery of reliable endophenotypes and biomarkers of illness and illness development.
Evidence for the Presence of a BD I Prodrome
Below, we summarize studies in various populations investigating the identification of a clinical high-risk state for BD I, focusing especially, but not exclusively, on pediatric data.
Offspring Samples
A first-degree BD I family history is a strong risk factor, as heritability rates range between 40% and 70% in twin and family studies, and the interaction of family environment, psychosocial stressors, and genetic loading also increases BD I risk. 37 Further, youth with MDD were significantly more likely to develop BD I if they had a BD I family history (50%, compared with 10%). 38 However, offspring of people with BD I are more likely than offspring of healthy families to develop any kind of psychiatric disorders, and although mood disorders are even more likely, BD I development has remained relatively low. [39] [40] [41] Thus, for youth with genetic loading for BD I, additional risk factors are needed. Those additional risk factors are also crucial because in community samples, the minority of adults with BD I has a first-degree family member with BD, 42 although prepubertal-onset BD I appears to have the highest familial loading. 43 Nevertheless, the genetic enrichment in offspring studies may not only increase the ultimate likelihood of BD I development in patients with mood symptoms but also enable a more targeted assessment of potentially more specific prodromal symptoms. Only few prospective BD I offspring studies are available. Compared with offspring of healthy parents, Duffy et al, 44, 45 in a 15-year follow-up study, described the early course and onset of illness in those offspring later developing BSDs as generally following a sequence from nonspecific psychopathology, followed by minor mood disturbances, depression, and finally hypomania or mania. However, not all subjects progressed through all stages, and BD I conversion rates have ranged from only 3% 44, 45 to 11% 46 during up to 15 years of followup. Among nonspecific psychopathology, sleep disturbances and anxiety disorders were particularly prevalent, and depression was the most common index episode. Somewhat surprisingly, no prepubertal onset (age under 12 years) was found in this sample, and the mean age of onset was 17 years. 47 Other groups also did not find transitions to mania prior to adolescence in BD I offspring, but rather reported elevated frequencies of a range of psychopathology, mostly anxiety and minor mood disturbances, with a subsequent development of major mood disorders. [48] [49] [50] Nevertheless, a recent, large, retrospective study from 7 international centres (n = 1665) identified a clustering of prepubertalonset illness in familial-type BD I. 43
Cyclothymic-Hypersensitive Temperament
Although adult studies showed some correlation between CHT traits (that is, a temperament characterized by mood swings and hypersensitivity), and BD I risk, [51] [52] [53] results are inconclusive and only few studies investigated temperamental features as risk syndromes for pediatric BD.
One prospective study 54 that focused on 80 youth with a current or past clinical diagnosis of MDD reported a 2-year conversion rate to BD (defined by a 2-day threshold for hypomania or mania) of 43%. In this study, youth with CHT, characterized by irritability, aggressive behaviours, anger outbursts, emotional hypersensitivity, and mood lability, showed more BSD conversions than those without CHT (68.8% and 15.2%, respectively). Further, people with CHT experienced more frequent and more severe mood episodes of either polarity. In addition, patients with CHT and higher likelihood of conversion more frequently had comorbid conduct disorder (55.3% and 15.2%, respectively) and suicidal ideation (80.9% and 36.4%, respectively). 54
Major Depressive Disorder
A survey by the NDMDA revealed that MDD was the first sign of BD I in almost 50% of patients. 5, 9 Moreover, conversion rates from MDD to BD I ranged between 7.7% and 49% in prospective studies, with higher rates among those with preadolescent-and adolescent-onset MDD and those with longer follow-up. 38, [55] [56] [57] [58] [59] [60] [61] However, reports of conversion from MDD to BD I below 7% also exist, 46, 62 and predictors for a differentiation between MDD and bipolar depression remain inconclusive. One study 38 of 60 hospitalized adolescents followed during 3 to 4 years found precipitous symptom onset, psychomotor retardation, and psychosis to significantly predict conversion to BD I. Additional predictive symptoms were depressed mood, self-reproach or self-pity, suicidal tendencies, weight gain, somatic preoccupations, diminished concentration, irritability, and demandingness. Precipitous MDD onset was also predictive of bipolar depression, compared with MDD, in a study 63 of adults. Moreover, another study 64 of depressed youth also found that psychotic features and psychomotor retardation, as well as treatment-induced hypomania or mania and (or) a BD I family history predicted BD I.
In a follow-up study 65 of a large community sample (n = 3206) in Germany, the incidence of mood disorders was studied in people initially aged 14 to 24 years who were interviewed 3 times after baseline, with a follow-up of 7.3 to 10.6 years at the last interview. A total of 3.6% of the initial MDD sample (n = 649) developed BD I or II by the third decade of life. Of note, the risk was highest in adolescentonset MDD before age 17, with a 9% conversion to BD I or II, without sex differences. Conversely, only 1% of adolescents and young adults who had a minor depressive episode at baseline (n = 327) converted to BD I or II.
Finally, a study 66 of 165 children 8 to 11 years old with mood disorders followed 37 children with DSD plus TMS, 13 with DSDs, and 115 with BSDs for 18 months. One-half of the patients each received MF-PEP right after baseline or only after a 1-year wait-list condition. TMSs were defined as more than 1 DSM-IV mania criterion, except for irritability, that is distinguishable from ADHD, presence of 1 to 3 maniclike episodes of moderate-to-severe intensity lasting more than 4 hours or presence of more than 2 brief episodes of 2-to 4-hours duration, evidence of functional impairment, and lack of having a BSD (that is, BD I, BD II, cyclothymia, or BD NOS). At 18 months, conversion to BSD (in patients with follow-up data) was significantly higher for the DSD plus TMS group (48.0%, that is, BD I, n =3 [8.1%], BD II, n = 5 [13.5%], BD NOS, n = 3 [8.1%], and substance-induced mood disorder, n = 1 [2.7%]), compared with the DSD group (12.5%, that is, BD NOS, n = 1). Patients in the wait-list condition experienced significantly higher conversions to BSD than those receiving MF-PEP immediately (60%, compared with 16%), indicating that therapy may prevent BSD development, and poorer baseline functioning was also associated with BSD conversion.
Taken together, these results suggest that, although a careful assessment of subthreshold mania symptoms in depressed youth is indicated, defined predictors for BSD risk are lacking. Further, other approaches for early identification are needed, as solely focusing on youth with MDD would systematically miss 50% of youth at risk who develop BD I without a first MDD episode.
Attenuated (Mania) Symptoms
The strategy of defining attenuated variants of cardinal and (or) diagnostic symptoms as an at-risk state for developing the full disorder has been fruitfully applied to the early identification of psychosis in samples consisting mainly of young adults, 11, 12 although approaches are also being applied to adolescents. 12, 67 Retrospective Studies. As the clinical high-risk psychosis field developed out of retrospective assessments of the symptomatic prodrome prior to first-episode psychosis, which informed the development of rating instruments and risk criteria that were then prospectively validated, 12 a similar approach is also being taken in the emerging BD prodrome field.
To date, still only few studies assessed the initial prodrome to mania. The largest retrospective study 9 of the NDMDA (n = 500) revealed that adults with a self-reported diagnosis of BD I experienced various prodromal symptoms. The most common symptoms included depressed mood or hopelessness (33%), mania and (or) hyperactivity (32%), decrease in sleep (24%), and mood swings (13%). As this study surveyed adults, it is unclear if these differ from prodromal symptoms in children and (or) adolescents. However, a chart review of Amish youth who developed BD I also lists mania-and depression-related symptoms, including depressed mood (53%), increased energy (47%), and decreased sleep (26%), as commonly reported prodromal symptoms in youth. 68 However, while adults reported nonspecific symptomatology (that is, anger, irritability, and psychotic symptoms) to a lesser degree (9%), these symptoms were a more significant part of the prodrome in youth (anger [38%], irritable mood [33%], bold, intrusive, and excessive behaviours or conduct difficulties [28% to 29%], crying spells [26%], and being overly sensitive [24%]). Another study 69 that asked parents via mailed questionnaires about symptoms during each year of their child's life, who had either a community diagnosis of BD I (n = 78), psychiatric diagnosis other than BD I (n = 38), or no psychiatric diagnoses (n = 82), extended the results above, reporting that irritability and (or) behavioural dyscontrol were the earliest features that distinguished children who later developed BD I from those who did not, while depressive and manic symptoms also distinguished the groups, but only in later childhood, that is, at age 7 to 8 years. Psychosis and suicidality were the last symptoms that distinguished the diagnostic groups at around age 9. Likewise, Correll et al 70 ). Further, again nonspecific symptoms were prominent, including decreased functioning (65%), mood lability (58%), anger outbursts (48%), social isolation (44%), and anxiety (42%). In this study, the mean prodromal phase before mania onset lasted 18 months, a time span allowing early identification efforts.
Additionally, Ritter et al 71 point to the significance of sleep disturbances for mood disorders in general, and for BSDs in particular, concluding that sleep disturbances did not begin in childhood, but emerged in adolescence, constituting a significant risk factor for BSDs.
Prospective Studies. Following a large cohort of college students for more than 8 years, Lewinsohn et a1 72 studied a subgroup of youth (mean baseline age 16.8, n = 48) with subsyndromal BD defined by a "distinct period of abnormally and persistently elevated, expansive, or irritable mood" p 282 plus more than 1 manic symptom, finding a very low conversion to BD (1/48 or 2.1%). Conversely, 40.9% of these youth developed MDD. However, in an analysis of the Munich sample (n = 3206) mentioned earlier, 65 the predictive value of the number and persistence of manialike symptoms for BD I or II development was assessed prospectively in a risk sample of 1565 subjects aged 14 to 21 at baseline and followed for 10 years. 73 The authors found a significant dose-response relation for persistence and number of both manic and depressive symptoms. Moreover, in 30% to 40% of people converting to BD I or II, the symptom progression could be traced back to subthreshold manic and depressive symptoms. 73 As reviewed above, only one of the cited studies investigating the BD prodrome assessed non-BD comparison groups regarding childhood symptoms. Including control groups is crucial, however, as prodromal symptoms may overlap between different disorders. This was also shown by 2 small case series of adolescents and young adults who fulfilled ultra-high risk for psychosis criteria (n = 47) 74 or met criteria for psychosis NOS (n = 26), 75 but developed BD I in 6.5% and 15.4% (19.2% when counting in BD NOS), respectively. In the second sample, anxiety symptoms distinguished patients developing BSDs from those developing nonaffective psychoses. 76 Further, in a prospective study 77 of adolescents fulfilling clinical high-risk criteria (that is, attenuated positive or negative symptoms) for schizophrenia spectrum psychoses, 8 adolescents who eventually developed BD I (n = 6, 5 with psychotic features) or BD NOS (n = 2) were compared on baseline symptom and neurocognitive measures to 24 adolescents who developed a schizophrenia spectrum psychotic disorder and 115 nonconverters. In this study, 77 BD and schizophrenia spectrum outcome patients differed from nonconverters, but not from each other, highlighting the need for BD-specific assessments and instruments. In addition, this study indicates that it is important to find predictors that distinguish between the development of affective and nonaffective psychotic disorders.
Two studies [78] [79] [80] used scores on the GBI to symptomatically define BD risk in youth. In a 5-year follow-up study, higher initial depression scores on the GBI differentiated people who later developed BD and other mood disorders from those without mood disorders, and those youth who converted from depression to BSDs from those who retained a depression diagnosis. 81 However, no validated cut-off scores are reported for the GBI yet to estimate the risk for BSDs in clinical practice. Further, in the ongoing Longitudinal Assessment of Mania Study, 82 children 6 to 12 years old are prospectively evaluated regarding correlates and the predictive utility of EMS, defined by a tentative cut-off score on the GBI of 12 or more, for future BD development. Preliminary results of 707 subjects showed that, compared with children with lower GBI scores, children with EMS had significantly more BSD (BD I: 10.6% and 5.8%, BD II: 0.5% and 0%, cyclothymia: 1.8% and 0%, and BD NOS: 12.1% and 2.3%), ADHD, and disruptive behaviour disorder diagnoses, without differences in depressive disorders. 83 However, conversion rates to BD are lacking.
Further, a certain profile of attention, aggression, and anxiety and (or) depression symptoms on the CBCL 84 has been discussed as a pediatric BD phenotype after a metaanalytic review of 7 studies. 85 However, despite some supportive findings, [86] [87] [88] [89] most subsequent cross-sectional and longitudinal studies [90] [91] [92] [93] [94] [95] [96] did not support the CBCL or the pediatric BD subscale sum score as standardized measures enabling the differentiation of BD from other psychopathology.
Bipolar Spectrum Disorders
BD NOS can be conceptualized as the most distal prodrome to BD I (unless one counts cyclothymia and BD II as prodromal states to BD I), as many, but not all, symptomatic criteria of BD I are fulfilled. In a landmark study 97 that prospectively studied 92 youth (mean age: 12.1 years) with clearly operationalized BD NOS, conversion rates after 2.5 and 4.0 years were 20% each to BD I and 10% and 18% to BD II, respectively. In this study, 97 BD NOS was defined by either one less Criterion B in the presence of irritability or expansive mood than required by DSM-IV, or a minimum of 4 days of at least 4 hours of suprathreshold criteria present cumulatively, rather than consecutively, plus functional impairment. However, as more than 80% of youth fulfilled all DSM-IV mania criteria at baseline, except for the duration criterion. Moreover, in younger subjects, ultradian cycling and very brief episodes are common. Therefore, it is still unclear if these youth had truly biological subsyndromal mania or if they had a potential pediatric mania subtype, with shorter episode duration, which morphed into a more adulthood pattern in patients who transitioned to mania as they biologically matured, expressing longer mood episodes. To date, conversion rates and patterns in youth or adults diagnosed with mood disorder NOS have not been reported. Correll et al 15 have proposed a symptom-based BD I and II staging model, with a progression from an early prodromal stage-consisting of subclinical, nonspecific, and attenuated mania symptoms-to a late prodromal stage-defined as BD NOS-and further to a subsyndromal (cylothymia and hypomania) and syndromal (BD I and II) stage. As suggested before, 15 these stages should be studied concurrently with a clinical, endophenotypic, and genetic approach.
Conceptual Models of the BD Prodrome
Based on data from the Australian early identification program, Bechdolf et al 18 proposed 3 prodromal criteria groups for BD I: subthreshold mania; depression plus cyclothymic features; and, depression plus genetic risk. A preliminary assessment of conversion rates in 173 patients aged 15 to 25 years categorized as at risk for BD by these criteria in retrospective chart reviews showed significantly more conversions (22.7% and 0.7%, P < 0.001, defined as hypomania-and [or] mania-related initiation or change in treatment) after 265.5 days (SD 214.7) in the group of atrisk subjects (n = 22) than the nonrisk subjects (n = 151). 18 Leopold et al 23 defined 6 domains of risk criteria for BD I that they suggest for prospective investigation: family history; impairment in psychosocial functioning; pronounced creativity; ADHD symptoms or diagnosis; substance use and (or) abuse; and, changes in sleep and circadian rhythm, mood swings and lability, anxiety, depressive, hypomanic or mixed symptoms, and dissociative symptoms. Similarly, Brietzke et al 98 defined 3 risk clusters for BD I, that is, a genetic risk, an environmental risk, and a profile of potential risk biomarkers.
Pavuluri 99 suggested that investigating endophenotypes, which could differentiate between childhood diagnoses that often precede BD (that is, ADHD and prepubertal MDD) and early, prodromal manifestations of BD, enhances early identification strategies. In addition, markers of emotional, social, and cognitive dysregulation family history and other neurobiological and temperamental markers should be studied.
Conclusions and Implications for Research and Clinical Practice
The search for symptoms and factors that can reliably predict BD I development in youth is still in its early stages. To date, several strategies point to phenomenological candidates that serve as the basis for the recent development of structured assessment tools and criteria for the BD I prodrome 18, 23, 70, [79] [80] [81] [82] [83] that will have to prove their predictive value. Prospective research will have to continue the refinement and definition of potential risk markers and clinical predictors. With the parallel advance of knowledge about BD I endophenotypes in youth, including genetics, neuroimaging, neurochemistry, and neurocognition, a combination of both, clinical and biological factors, is expected to enhance presyndromal identification of BD I. 15 As the main age of onset of the first illness signs appears to mainly span adolescence and early adulthood, close collaboration between or, ideally, integration of child and adolescent psychiatric services with adult psychiatric services should be attempted in the research and optimal care of at-risk youth. Further, as identified youth with clinical risk status for BD I will include patients at true risk for other psychiatric disorders and outcomes, a more inclusive research approach covering the assessment and treatment of a broader range of emerging psychopathology should be considered.
Until a more precise risk prediction can be achieved, clinicians should carefully assess current putative risk symptoms for BD I (that is, depressive and attenuated manialike symptoms, CHT traits, decline in social and role functioning, ADHD, and DBD) in patients with mood spectrum presentations (online eTable 3), particularly in youth with MDD or a BSD family history. This information should be used to aid clinical decision making regarding early diagnosis and treatment. In youth at risk for BD, treatment options should be weighed carefully and ADs may need to be avoided in favour of mood stabilizer treatment with AD activity, or surveillance be increased if ADs are started. In general, as proposed for psychotic disorders, 14 a staged treatment approach to BD I risk constellations that uses benign, nonpharmacologic interventions first and increases the treatment-related risk as the risk and severity of the suspected or diagnosed conditions increase, 25 is considered the most appropriate approach, especially in youth who are even more sensitive to medication adverse effects. 100, 101 In this regard, pilot data 66 on the efficacy of psychosocial interventions in youth with attenuated manialike symptoms are encouraging but require additional study.
